静脉注射人免疫球蛋白临床应用的不良反应之三年回顾性研究

doi:10.5246/jcps.2019.01.007

中国药学(英文版) ›› 2019, Vol. 28 ›› Issue (1): 56-61.DOI: 10.5246/jcps.2019.01.007

• 【药事管理与临床药学专栏】 • 上一篇下一篇

静脉注射人免疫球蛋白临床应用的不良反应之三年回顾性研究

邵淑容^1*, 郭卫^2,3

1. 宁波市妇女儿童医院药剂科, 浙江宁波 315012
2. 温州医科大学附属眼视光医院神经分子神经药理学研究组, 浙江温州 325035
3. 省部共建眼视光学和视觉科学国家重点实验室, 浙江温州 325035

收稿日期:2018-10-07 修回日期:2018-11-12 出版日期:2019-01-27 发布日期:2018-12-05
通讯作者: Tel.: +86-0574-83887054, E-mail: shaoshurong1988@163.com
基金资助:
Wenzhou Science and Technology Program (Grant No. Y20160012).

Adverse events of intravenous immunoglobulin infusions: a three-year retrospective study in China

Shurong Shao^1*, Wei Guo^2,3

1. Pharmaceutical department, Ningbo Women & Children’s Hospital, Ningbo 315012, China
2. Molecular Neuropharmacology Laboratory, School of Optometry and Ophthalmology and Eye Hospital, Wenzhou Medical University, Wenzhou 325035, China
3. State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health, China and Zhejiang Provincial Key Laboratory of Ophthalmology and Optometry, Wenzhou 325035, China

Received:2018-10-07 Revised:2018-11-12 Online:2019-01-27 Published:2018-12-05
Contact: Tel.: +86-0574-83887054, E-mail: shaoshurong1988@163.com
Supported by:
Wenzhou Science and Technology Program (Grant No. Y20160012).

摘要/Abstract

摘要：

本文主要描述静脉注射人免疫球蛋白在儿童临床应用中常见的不良反应。收集浙东地区最大的儿童医院宁波市妇女儿童医院2015年至2017年所有应用IVIG的情况, 并对发生不良反应的患儿的临床数据进行记录、归纳及总结。结果发现, 三年间共有2100名患儿应用了静脉注射人免疫球蛋白, 其中共计10名儿童发生药物不良反应, 且1至3岁患儿的发生率最高(40%), 其中7名患儿的用药指征为川崎病及重症肺炎(70%)。另外, 其中8名患儿出现皮疹, 5名患儿存在胸痛, 4名患儿伴有面色发绀。不良反应最常发生于注射开始的30 min内, 且于大剂量应用时更容易发生。鉴于2015–2016年该药不良反应发生率高于往年, 医院2017年更改不同品牌的IVIG, 该药的不良反应发生率从1.39%降至0.13%。在我们的研究中, 0.48%的应用IVIG的患儿产生不良反应, 过敏样反应是发生率最高的不良反应, 且症状通常出现在开始滴注的30 min内, 且受用药剂量、患儿的免疫状态、用药的指征、以及药品品牌所影响。

关键词: 静脉注射人免疫球蛋白, 药物不良反应, 儿童, 回顾性研究

Abstract:

Intravenous immunoglobulin (IVIG) is biological product, which is extensively used in pediatric patients, with high adverse effects on children among different brand preparations. In the present study, we aimed to describe the adverse events of pediatric patients given IVIG infusions in China. Data were collected from all patients receiving IVIG infusion at the largest children’s hospital in Ningbo of China form January 2015 to December 2017. Descriptive statistics was used. A total of 2100 patients received IVIG infusion. All the patients who experienced adverse reactions were children (0.48%), with the highest frequency of infusion among those age 1 to 3 years old (40%). Among 10 infusions with adverse reactions, the most common indication was Kawasaki disease (40%) followed by severe pneumonia (30%). Rash was the most common adverse event (80%), followed by chest pain & cough (50%) and cyanosis (40%). Adverse events were observed to occur most frequently within 30 min from onset of infusion. Most of the reactions occurred with the large dose and the indications of used for. Since the hospital changed the brand, the incidence of adverse reactions was decreased from 1.39% to 0.13%.In this study, 0.48% of pediatric patients given IVIG infusions experienced adverse events. Anaphylactoid reaction was the most common manifestation. Symptoms occurred within 30 min from onset of infusion, which were affected by the dose, the value of lgE, the indications and the different brands.

Key words: Intravenous immunoglobulin, Adverse reactions, Children, Retrospective study

中图分类号:

R969

Supporting:

邵淑容, 郭卫. 静脉注射人免疫球蛋白临床应用的不良反应之三年回顾性研究[J]. 中国药学(英文版), 2019, 28(1): 56-61.

Shurong Shao, Wei Guo. Adverse events of intravenous immunoglobulin infusions: a three-year retrospective study in China[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(1): 56-61.

参考文献

[1] Sewell, W.A.; Jolles, S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002, 107, 387-393.

[2] Diep, B.A.; Le, V.T.; Badiou, C.; Le, H.N.; Pinheiro, M.G.; Duong, A.H.; Wang, X.; Dip, E.C.; Aguiar-Alves, F.; Basuino, L.; Marbach, H.; Mai, T.T.; Sarda, M.N.; Kajikawa, O.; Matute-Bello, G.; Tkaczyk, C.; Rasigade, J.P.; Sellman, B.R.; Chambers, H.F.; Lina, G. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci. Transl. Med. 2016, 8, 357ra124.

[3] Burns, J.C.; Franco, A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev. Clin. Immunol. 2015, 11, 819-825.

[4] Choi, H.S.; Ji, M.H.; Kim, S.J.; Ahn, H.S. Platelet count recovery after intravenous immunoglobulin predicts a favorable outcome in children with immune thrombocytopenia. Blood Res. 2016, 51, 95-101.

[5] Brenton, J.N.; Banwell, B.L. Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. Neurotherapeutics. 2016, 13, 84-95.

[6] Palabrica, F.R.; Kwong, S.L.; Padua, F.R. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac. Allergy. 2013, 3, 249-256.

[7] Wada, Y.; Kamei, A.; Fujii, Y.; Ishikawa, K.; Chida, S. Cerebral infarction after high-dose intravenous immuno-globulin therapy for Kawasaki disease. J. Pediatr. 2006, 148, 399-400.

[8] Kahwaji, J.; Barker, E.; Pepkowitz, S.; Klapper, E.; Villicana, R.; Peng, A.; Chang, R.; Jordan, S.C.; Vo, A.A. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin. J. Am. Soc. Nephrol. 2009, 4, 1993-1997.

[9] Alliot, C.; Rapin, J.P.; Besson, M.; Bedjaoui, F.; Messouak, D. Pulmonary embolism after intravenous immunoglobulin. J. R. Soc. Med. 2001, 94, 187-188.

[10] Dalakas, M.C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994, 44, 223-226.

[11] Siegel, J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005, 25, S78-S84.

[12] Singh-Grewal, D.; Kemp, A.; Wong, M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch. Dis. Child. 2006, 91, 651-654.

[13] Yi, Z.M.; Tang, S.D.; Liu, F.; Zhai, S.D.; Jiao, L.G. Evaluation on telbivudine-associated rhabdomyolysis. J. Chin. Pharm. Sci. 2016, 25, 66-72.

静脉注射人免疫球蛋白临床应用的不良反应之三年回顾性研究

Adverse events of intravenous immunoglobulin infusions: a three-year retrospective study in China

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	武海艳, 张翔, 丁珊珊, 张国华, 唐琳琳, 唐琳. 儿童难治性支原体肺炎的抗支原体药物治疗进展[J]. 中国药学(英文版), 2022, 31(5): 334-342.
[2]	严荧燕, 毛佩芝, 陈漪, 沈珑慧. 儿童医院门急诊布洛芬和对乙酰氨基酚交替使用分析[J]. 中国药学(英文版), 2022, 31(5): 369-373.
[3]	罗晓, 邵宏. 伊曲康唑治疗EICU侵袭性真菌感染的疗效与安全性分析[J]. 中国药学(英文版), 2015, 24(10): 678-682.